Feedback Share Discussion Threads

[botak54] 29/9/2019 13:16

Bi Polar Botack eh ! Well thats a a bang on diagnosis Doctor , Got me in one
As for - I think on balance Botak has bought back his trading pot on Friday lol,
Mhhhh keep thinking what you want if it helps

[ducatiman] 29/9/2019 13:10

Great info Ged, welcome back and pleased the thread is back! Thank you.

[ged5] 29/9/2019 13:06

Read more carefully, hazl. I specifically said the IQAI board. Post 750 is on this thread.

[hazl] 29/9/2019 13:05

Yes I had a genuine interest but post 750 was to someone else.

[hazl] 29/9/2019 13:04

Ah here we are that was before I bought in.

hazl - 29 Jul 2019 - 08:09:33 - 1567 of 3314 FEEDBACK plc Medical Imaging Technology - FDBK
I got some at last GED5 .
thanks for your input.
I thought that we would have till September but suddenly it all kicked off!

First time I got FDBK

[ged5] 29/9/2019 13:03

No, it was your question that I responded to..
Why severe? You seemed to have a genuine interest.

[ged5] 29/9/2019 13:00

On Point 4
Logic would suggest that Texrad now has a better chance of approval now that its been granted to Stone Checker.

On Point 1

The only hint of payments for Stone Checker can be inferred from IQAI's Annual Report and Interim Report.

The ONLY sale of Stone Checker was in November 2018

The Annual Report was to Year end December 2018 and so included the sale of Stone Checker.

The revenue was £164,971 up to 31st December 2018
The Revenue for the half year is 126,00 up to 30th June 2018

The only revenue I can find from 30th June to 31st December 2018 is the sale of Stone Checker.

So I'm assuming that Stone Checker sales are at most £38,000.
I still haven't found what percentage royalties we are due but at 10% £3800 at most, 20% £7600.

In other words IQAI are going to have to have very many sales of Stone Checker for FDBK to make any significant revenue.

Bring on Bleepa Contracts and TexRAD innovative ideas.

[hazl] 29/9/2019 12:41

Questioned by hazl seems a bit severe?
Perhaps taken an interest is more like it. 8-)

Ah looked back and it was post 750 so must have been LR2 or Hedgehog post that you were responding to.

[hazl] 29/9/2019 12:39

I think there's room for both.
FDA is quite an accolade for IQAI and though I am not currently in, I had a nice trade on Friday.... got in about 6.55 or thereabouts.
I was in and out sometime ago at about 4p .

As I have said before, I am an investor here, all being well because of the many uses I see for Bleepa.
Anything else is icing on the cake.
Despite Friday's shenanigans,it was quick to recover afterwards and I think we are in a rising trend.

IMO

[ged5] 29/9/2019 12:25

And later this:-

The 4 points were the 4 questions I had. I found the answer to No 2. T. Brown answered No.3, he didn't answer No.1.

No. 4 was asked to FDBK but they don't answer.

[ged5] 29/9/2019 12:24

Then on being questioned by Hazl I posted this:-

I see that in May 2016 FDBK agreed to sell its 50% equity interest in Stone Checker Software Ltd ('Stone Checker') to Free Association Books Limited, a company connected to one of Feedback's directors, Trevor Brown, for a cash consideration of £46,000 (the "Disposal").

Then in June 2017 8,000,000 ordinary shares of £0.01 each in the capital of the Company (the Consideration Shares) to the shareholders of Stone Checker Software Limited (the Target) in connection with the acquisition by the Company of the Target (the Acquisition). I've seen elsewhere the share price was 3p.

I'm not sure who held the other 50% at this time.

I must admit I'm not really interested in IQAI other than:

1. How much royalties FDBK receives on any sales of Stonechecker
2. What are the circumstances where TexRAD may terminate this agreement
3. Can Stonechecker receive FDA approval before Texrad
4. If Stonechecker receives FDA approval will it improve Texrad's chance of approval?

Answer to No. 2:-

TexRAD Limited is entitled to terminate the Patents Licence if:

(1) it is determined by an expert that the Target has without legitimate reason failed to use diligent and reasonable efforts to develop and commercially exploit the TexRAD Plug-in;

(2) the Target is in material breach of the Patents Licence and such breach is not remedied, if capable of remedy, within 30 days; or

(3) if the Target becomes insolvent.

The Patents Licence requires the Target to pay TexRAD Limited royalty payments. Accordingly, if the Target failed to meet these payments and failed to remedy this breach within 30 days, and this was determined to be a material breach of the Patents Licence, TexRAD would be entitled to terminate the Patents Licence. Accordingly, a key risk is that the Patents Licence is terminated.

[ged5] 29/9/2019 12:18

Back in May I posted this on the IQAI board:-

There was an overlap of interest with Stonechecker between FDBK and IQAI. There were some questions for which I wanted the answers.

One of those questions was whether Stonecheckers FDA approval was dependent on Texrad gaining approval.

Earlier this week I tried emailing IQAI but the emails were not sending. I tried again yesterday.

In the early hours of this morning I received the reply:-

"Stonechecker approval is not related or dependant on any other application including any by Texrad"

Thank you Mr Brown for taking the time to reply.

[botak54] 29/9/2019 10:54

Morning Bob
No Worries, Anything IQAI can do we can do better ! Well I hope prospective incoming believes that and at the end of the day its nothing about shooting the sh-t on here its about inducing coaxing a feeding frenzy from exited investors , Only thing the BOD have to do ( at this moment in time ) is just throw them anything that resembles successes , IQAI has done all the hard work for them .,,Just need to jump on the bandwagon

[bobd29] 29/9/2019 10:43

Morning Bo, trading volume next week will be interesting. I think an announcement is due very soon and as leaky as this ship is volume could be an indicator of timing. Market savvy may not be their strong suite but these are very clever people and I believe they know they have potentially market changing products. I take TO and the good Prof to steer the company to success, just hope I have the time to see it happen.

[botak54] 29/9/2019 09:18

As much as that is the basics and part an parcel of running a company listed on AIM , The BOD are No Comprende on that one,

Sadly


, its not even part of there repertoire

[hope67] 29/9/2019 08:56

Iqai had big buyers taking it up Friday think that will continue its rise Monday the herd is behind it waiting on potential revenue rns. Sentiment plays a huge part take note bod.

[hazl] 29/9/2019 07:30

IQAI has been great, and I believe, Trevor Brown.

An exciting share.

[lr2] 29/9/2019 01:13

Also worth checking out is Dr. Qu Li, executive director at Peterhouse. It's worth researching her part in the demise of MG Rover and the sale of the LDV Vans division to China. Qu Li is part of the 3 man board over at IQAI alongside near 30% holder Trevor Brown. It doesn't take too much imagination to see what the end result might be there.

[hope67] 29/9/2019 00:42

Interesting Botak thanks

[botak54] 29/9/2019 00:28

Hope , There has been various entity,s not only shorting here but trading to control , OK Now with 540M not so eazy , Unless you control MM,s , Peterhouse and there Assassin Duncan Vassey are active with FDBK

[ducatiman] 28/9/2019 20:34

Stonechecker, lol. That is not what will drive this company forward. Certainly caused a volume spike though! What will happen when we get some relevant good news. GLA,

[hazl] 28/9/2019 20:22

It's not mine though hope67.